TY - JOUR
T1 - Dangerous surgical scavenger hunt
T2 - The complicated course of a patient with left ventricular assist device and end-stage renal disease undergoing reconstructive flap surgery
AU - Freundt, M.
AU - Haneya, A.
AU - Schmid, C.
AU - Hirt, S.
N1 - Publisher Copyright:
© The Author(s) 2014.
PY - 2015/9/19
Y1 - 2015/9/19
N2 - Patients with left ventricular assist devices (LVADs) who develop stage IV sacral pressure sores (SPS) have an increased procedural risk. We present the complications, including severe intra- and postoperative bleeding, diarrhea with metabolic acidosis, volume loss and acute on chronic renal failure, flap dehiscence and late LVAD outflow cannula thrombosis, in a 54-year-old male who underwent diverting ileostomy (DI) and subsequent fasciocutaneous flap (FCF) surgery for stage IV SPS while supported with an LVAD. Our experience suggests that, despite continuous heparinization, life-threatening thrombotic complications, such as device clotting, can occur. Therefore, the benefit of intervention has to outweigh the risk of bleeding, which should be managed with meticulous surgical technique and substitution of red blood cells rather than the reversal of heparinization or the substitution of clotting factors. Continuation of double anti-platelet therapy should also be considered.
AB - Patients with left ventricular assist devices (LVADs) who develop stage IV sacral pressure sores (SPS) have an increased procedural risk. We present the complications, including severe intra- and postoperative bleeding, diarrhea with metabolic acidosis, volume loss and acute on chronic renal failure, flap dehiscence and late LVAD outflow cannula thrombosis, in a 54-year-old male who underwent diverting ileostomy (DI) and subsequent fasciocutaneous flap (FCF) surgery for stage IV SPS while supported with an LVAD. Our experience suggests that, despite continuous heparinization, life-threatening thrombotic complications, such as device clotting, can occur. Therefore, the benefit of intervention has to outweigh the risk of bleeding, which should be managed with meticulous surgical technique and substitution of red blood cells rather than the reversal of heparinization or the substitution of clotting factors. Continuation of double anti-platelet therapy should also be considered.
UR - http://www.scopus.com/inward/record.url?scp=84939535310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939535310&partnerID=8YFLogxK
U2 - 10.1177/0267659114560043
DO - 10.1177/0267659114560043
M3 - Article
C2 - 25378418
AN - SCOPUS:84939535310
SN - 0267-6591
VL - 30
SP - 469
EP - 471
JO - Perfusion (United Kingdom)
JF - Perfusion (United Kingdom)
IS - 6
ER -